Search bioRxiv⌕ Search

bioRxiv · 10.64898/2026.10.28.762676

Latent Transforming Growth Factor Binding Protein ? 2 promotes microfibrillar TGF-? bioavailability to drive pathologic fibrosis in remote regions of infarcted hearts

Abstract

Myocardial infarction (MI) initiates ventricular remodeling that extends beyond the infarct into remote, viable myocardium, where diffuse extracellular matrix (ECM) remodeling and stiffening contribute to progressive dysfunction and heart failure. Latent transforming growth factor binding protein 2 (LTBP2) is an injury-induced, microfibril-associated ECM glycoprotein that, among the LTBP family, does not covalently bind latent TGF-?. We asked whether LTBP2 regulates remote remodeling after MI, and how a protein lacking latent TGF-??binding capacity could influence TGF-??dependent fibrosis. Wild-type and Ltbp2-null mice underwent permanent coronary ligation or sham surgery and were followed for 28 days by echocardiography and speckle-tracking strain analysis. Remote myocardium was assessed by histology, atomic force microscopy, and quantitative proteomics. Mechanism was interrogated in primary cardiac fibroblasts using a TGF-? reporter assay. Sufficiency was tested with a fibrillin-1?binding module of LTBP2 delivered as purified protein or by lentiviral expression. LTBP2 was induced in injury-activated cardiac fibroblasts and localized to infarct and remote myocardium by 7 days post-MI. Ltbp2 deletion improved 28-day survival (P=0.0272) where Ltbp2-null hearts showed preserved ejection fraction and faster diastolic strain rates, with protection concentrated in segments remote from the infarct. Remote myocardium contained less interstitial collagen and was significantly less stiff. Proteomic profiling showed enrichment of ECM organization and TGF-??responsive programs in wild-type hearts that was attenuated in knockouts. In fibroblasts, loss of LTBP2 increased LTBP1 matrix incorporation and shifted TGF-? from the soluble to the matrix-bound compartment; conversely, the minimal LTBP2 module bound fibrillin-1 directly and mobilized latent TGF-? from established matrix within 20 minutes. LTBP2 drives maladaptive remodeling of remote myocardium after MI by limiting matrix sequestration of latent TGF-? and expanding the activatable pool, resolving how an LTBP that does not bind latent TGF-? amplifies TGF-??dependent fibrosis. LTBP2 and its fibrillin-1 interaction surface may be tractable targets.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ehsan, F., Di Paola, M., Dewar, M., Zhang, H., Kuzmanov, U., Zhou, Y.-Q., Reitz, C. J., Shah, H., Wang, T., Liu, J., Izumi, A., Hu, R., Hendy, J., Younesi, F. S., Friedberg, M. K., Billia, F., Nakamura, T., Hinz, B., Mecham, R. P., Gramolini, A. O., Heximer, S. P.. 2026-11-03. Latent Transforming Growth Factor Binding Protein ? 2 promotes microfibrillar TGF-? bioavailability to drive pathologic fibrosis in remote regions of infarcted hearts. https://doi.org/10.64898/2026.10.28.762676

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Age-related biological dysregulation quantified using metabolomics is composed of distinct subsystems with synergistic associations to health outcomes: An analysis of the Canadian Longitudinal Study on Aging

Resilience is a fundamental component of healthy aging, whereby an organism can efficiently respond to external stressors and return to a resting biological and physiological state, known as homeostasis. This capacity declines with age in a heterogenous manner and is aggravated by biological dysregulation, a detrimental state broadly associated with health risk factors and poor outcomes. However, the underlying structure of dysregulation remains unclear, particularly in the context of older adult health trajectories. Here, we take a novel systems-based approach to the quantification of dysregulation using metabolomic data from n=9,992 older adults enrolled in the Canadian Longitudinal Study on Aging. We show that dysregulation across different biological systems is heritable, and exhibit distinct associations with health risk factors, indicators and outcomes, and DNA methylation patterns. Importantly, the effect of systems-specific dysregulation is cumulative, resulting in a significantly higher risk of disease incidence and death in older adults. Our findings broaden our understanding of biological dysregulation as a health state and demonstrate the value of system-specific dysregulation for effective strategies in personalized medicine and risk stratification.

physiology↗

An LRH-1 agonist reverses hepatic metabolic dysfunction in obesity

Liver receptor homolog-1 (LRH-1; NR5A2) is a nuclear receptor that controls metabolic gene programs important for liver health. Here, we address two challenges with dissecting ligand-driven LRH-1 metabolism in vivo. First, we generate ME610, a potent LRH-1 agonist with favorable pharmacokinetic properties. Second, we engineer Nr5a2humLBD mice, edited to recapitulate the ligand response of the human receptor. ME610 dose-dependently induces LRH-1 target genes and reduces triglycerides in livers of Nr5a2humLBD mice. In a mouse model of diet-induced obesity (DIO), ME610 dramatically improves insulin sensitivity and reduces liver fat. Multi-omics integration of transcriptomics, lipidomics, and metabolomics data demonstrates a coordinated reversal of DIO-induced hepatic metabolic stress via changes in lipid, amino acid, and energy metabolism, with peroxisomal lipid metabolism emerging as a central process correlated to efficacy. These studies uncover new pathways through which LRH-1 regulates metabolism and demonstrate the therapeutic potential of synthetic LRH-1 agonists in obesity-associated metabolic diseases.

physiology↗

SCN- induces prestin contraction through reduced intermonomer angles and a modified transporter like movement of each monomer.

Prestin is the membrane based molecular motor responsible for outer hair cell electromotility that expands and contracts in response to transmembrane voltage. How voltage brings these about is unknown but cryoEM structures in the presence of ligands has led to the extrapolation of structures with the transporter cycle and its expansion contraction coupling. We find prestin to adopt novel increasingly contracted states that are brought about by a reduced intermonomer angles in the obligate dimers and a transmembrane contraction of each monomer at its cytoplasmic half in the presence of SCN-. These changes are associated with a loss in the intermonomer beta sheet at its N terminus. There is a hyperpolarizing shift in Vh along with increased affinity for SCN-. SCN- binding at the internal binding site likely cause the structural changes since they are reversed by SCN- displacement by salicylate.

physiology↗